Table 4

Disease activity analyses after the first and second dose of the Sinovac-CoronaVac vaccine in patients with rheumatoid arthritis

After first dose (D28)P valueAfter second dose (D69)P valueAt any momentP value
ΔDAS28-CRP ≥1.2 or ΔDAS28-CRP ≥0.6 + DAS28-CRP >3.2MTX-hold (n=60)7 (11.7)0.57612 (20)0.18822 (36.7)0.094
MTX-maintain (n=69)6 (8.7)8 (11.6)16 (23.2)
CDAI >10MTX-hold (n=60)13 (21.7)0.12219 (31.7)0.01123 (38.3)0.024
MTX-maintain (n=69)8 (11.6)9 (13)14 (20.3)
Patient impression of disease flareMTX-hold (n=60)6 (10)0.5778 (13.3)0.04414 (23.3)0.022
MTX-maintain (n=69)5 (7.2)2 (2.3)6 (8.7)
  • For safety analyses, all patients who adhered to the protocol were included.

  • Results are expressed in n (%) and compared with χ2 or Fisher’s exact test, as appropriate, as two-sided analyses.

  • CDAI, Clinical Disease Activity Index; D28, day 28; D69, day 69; DAS28-CRP, Disease Activity Score with 28 joints and C reactive protein; MTX, methotrexate; ΔDAS28-CRP, variation of DAS28-CRP score.